NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Invivyd, Inc. (IVVD) Stock Analysis

Invivyd, Inc. (IVVD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IVVD

$0.64

+$0.00 (+0.42%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IVVD with… →

IVVD Key Statistics

As of Oct 21, 2026
Trading
Open
$0.66
Previous Close
$0.64
Day's Range
0.64–0.69
52-Week Range
0.53–3.07
Volume
6.01M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.95
Valuation
Market Cap
$188.44M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.23
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.33
Financials (FY)
Revenue (FY)
$53.43M+110.47%
Net Income (FY)
−$52.49M
Profit marginThe share of revenue left as profit after all costs and taxes.
−183.90%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
294.76M
1-Year Return
−68.66%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
5.03M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IVVD closed at $0.64, −68.66% over 1 year.

Invivyd, Inc. (IVVD) has a market capitalization of $188.44M.

In fiscal 2025, IVVD reported revenue of $53.43M.

IVVD Stock Return by Calendar Year

Invivyd, Inc. (IVVD) return since Aug 2021: what $10,000 became

1 year
$10,000 $3,134
−68.66%
5 years
$10,000 $190
−98.10%
Since Aug 2021
$10,000 $306
−96.94%

If you had invested $10,000 in Invivyd, Inc. (IVVD) at the close on August 6, 2021, the earliest close on record here, it would have been worth $306 at the close on October 21, 2026: −96.94% in total, −48.80% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−74.12%
2025+457.56%
2024−88.76%
2023+162.67%
2022−79.34%
2021 (partial year)−65.23%

As of October 21, 2026.

IVVD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$53.43M−$52.49M−98.2%
2024$25.38M−$169.93M−669.4%
2023$0.00−$198.64M—
2022$0.00−$241.32M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$53.43M$49.68M−$55.56M−$52.49M−98.2%
2024$25.38M$23.77M−$176.88M−$169.93M−669.4%
2023$0.00$0.00−$207.78M−$198.64M—
2022$0.00—−$226.26M−$241.32M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IVVD Valuation vs Biotechnology Median

Median of 608 stocks
MetricIVVDBiotechnology medianvs median
P/S ratio3.2313.300.2x the median
Profit margin−183.90%−38.31%145.6 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 19 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Invivyd, Inc. (IVVD) is capitalised at $188.44M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 122.

Over the past 52 weeks the price has ranged from $0.53 to $3.07. IVVD last closed at $0.64 on October 21, 2026. That is $0.00 (+0.42%) against the previous close. The latest close sits 21.08% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $53.43M. That is +110.47% against the prior fiscal year, when revenue was $25.38M. The same year closed with a net loss of $52.49M. Profit margin runs at −183.9%. That is 145.6 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −0.33.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $53.43M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 3.23. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −68.66%. Across 5 years the annualized return works out at −54.74%. Beta against the wider market is reported at 0.95. Daily returns over the trailing 5 years annualize to a volatility of 176.09%.

Growth & Income

No dividend is on file for IVVD.

2026 is still running; the total return is −74.12% year to date. Across the complete calendar years on file, 2025 returned +457.56% and 2024 returned −88.76%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Invivyd, Inc. (IVVD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Invivyd, Inc. IVVD $188.44M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Invivyd, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Invivyd, Inc.

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.

Visit website →